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Background
In previous phase 1–2 clinical trials involving older adults, a subunit vaccine contain-
ing varicella–zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) 
had a clinically acceptable safety profile and elicited a robust immune response.
Methods
We conducted a randomized, placebo-controlled, phase 3 study in 18 countries to 
evaluate the efficacy and safety of HZ/su in older adults (≥50 years of age), stratified 
according to age group (50 to 59, 60 to 69, and ≥70 years). Participants received two 
intramuscular doses of the vaccine or placebo 2 months apart. The primary objec-
tive was to assess the efficacy of the vaccine, as compared with placebo, in reducing 
the risk of herpes zoster in older adults.
Results
A total of 15,411 participants who could be evaluated received either the vaccine 
(7698 participants) or placebo (7713 participants). During a mean follow-up of 
3.2 years, herpes zoster was confirmed in 6 participants in the vaccine group and 
in 210 participants in the placebo group (incidence rate, 0.3 vs. 9.1 per 1000 person-
years) in the modified vaccinated cohort. Overall vaccine efficacy against herpes 
zoster was 97.2% (95% confidence interval [CI], 93.7 to 99.0; P<0.001). Vaccine ef-
ficacy was between 96.6% and 97.9% for all age groups. Solicited reports of injec-
tion-site and systemic reactions within 7 days after vaccination were more frequent 
in the vaccine group. There were solicited or unsolicited reports of grade 3 symp-
toms in 17.0% of vaccine recipients and 3.2% of placebo recipients. The proportions 
of participants who had serious adverse events or potential immune-mediated dis-
eases or who died were similar in the two groups.
Conclusions
The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who 
were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or 
older was similar to that in the other two age groups. (Funded by GlaxoSmithKline 
Biologicals; ZOE-50 ClinicalTrials.gov number, NCT01165177.)
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Herpes zoster, or shingles, results from the reactivation of latent varicella–zoster virus (VZV) in the dorsal-root or 
cranial-nerve ganglia, usually decades after pri-
mary infection.1,2 Herpes zoster is characterized 
by a vesicular rash with a unilateral and derma-
tomal distribution and is almost always accom-
panied by pain. More than 90% of adults have 
been infected with VZV and are at risk for herpes 
zoster.3,4 Although herpes zoster is most frequent 
in adults who are 50 years of age or older owing 
to immunosenescence, it can occur at any age, 
especially when cell-mediated immunity is de-
creased as a result of disease or drug therapy.1,3,5 
Common complications, such as postherpetic 
neuralgia, are more frequent and severe with in-
creasing age.1,4,5
A live-attenuated vaccine against herpes zoster 
(Zostavax, Merck) containing the Oka VZV strain 
is licensed for use in adults who are 50 years of 
age or older.1,6 Zostavax showed 51.3% efficacy 
against herpes zoster and 66.5% efficacy against 
postherpetic neuralgia in participants who were 
60 years of age or older.7 However, its efficacy 
against herpes zoster decreased with age (from 
69.8% in adults between the ages of 50 and 59 
years to 37.6% in those ≥70 years of age),7,8 and 
it is contraindicated for use in persons with im-
munosuppression in whom live-attenuated vac-
cines may cause disease.1,6
Recombinant subunit vaccines are an alterna-
tive to live-attenuated vaccines and may also be 
suitable for persons with immunosuppression 
because the risk of disease resulting from repli-
cation of the vaccine virus is prevented.9,10 An 
investigational recombinant subunit vaccine con-
taining VZV glycoprotein E and the AS01B adju-
vant system (called HZ/su, GlaxoSmithKline Bio-
logicals) is being evaluated for the prevention of 
herpes zoster in older adults. VZV glycoprotein 
E was selected as a candidate vaccine antigen 
because it is essential for viral replication and 
cell-to-cell spread and is a primary target of 
VZV-specific immune responses.11-15 The anti-
gen was combined with AS01B because this adju-
vant system promotes strong CD4+ T-cell and 
humoral immune responses against recombinant 
proteins.16-20 Previous phase 1–2 clinical trials 
that were conducted in older adults and in per-
sons with immunosuppression showed that HZ/su 
had a clinically acceptable safety profile and 
elicited a robust immune response that persisted 
for at least 3 years in older adults.19,21-24 In light 
of these results, we conducted a phase 3 trial, 
called the Zoster Efficacy Study in Adults 50 
Years of Age or Older (ZOE-50), to assess wheth-
er two doses of HZ/su reduce the risk of herpes 
zoster in adults 50 years of age or older.
Me thods
Study Design and Oversight
ZOE-50 is an ongoing, randomized, placebo-con-
trolled study conducted in 18 countries in Eu-
rope, North America, Latin America, and Asia–
Australia. It was designed to evaluate the efficacy, 
immunogenicity, and safety of the HZ/su vaccine 
in adults who are 50 years of age or older. The 
study protocol was approved by the appropriate 
independent ethics committee or institutional 
review board at each study center. Written in-
formed consent was obtained from all partici-
pants before study entry.
The study is being conducted in accordance 
with the provisions of the Declaration of Hel-
sinki and the International Conference on Har-
monisation–Good Clinical Practice guidelines. 
During the course of the study, potential re-
search compliance issues were investigated and 
appropriate actions were taken when needed. 
(Details are provided in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org.)
The study was monitored by an independent 
data and safety monitoring committee, which 
met regularly during the course of the study to 
review all safety data in an unblinded manner 
and which identified no safety concerns. The 
primary efficacy end point has been reached and 
is reported here. Because the study is ongoing to 
allow for collection of data that are required to 
assess several secondary end points, the authors 
remain unaware of participant-level data at this 
stage of the analysis.
Therefore, all statistical analyses were per-
formed by external statisticians. Data regarding 
study results were screened by a firewall team 
consisting of scientists employed by the sponsor, 
GlaxoSmithKline Biologicals, who were not in-
volved in the conduct of the trial, and only data 
that would not risk participant- level unblinding 
were shared with the authors. (A more detailed 
description of the methods that are being used 
in the study is provided in the Supplementary 
The New England Journal of Medicine 
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Appendix and the study protocol, available at 
NEJM.org.)
Study Participants
Participants who were 50 years of age or older 
were eligible for inclusion unless they had a his-
tory of herpes zoster, were previously vaccinated 
against varicella or herpes zoster, or had an im-
munosuppressive condition. The complete list of 
inclusion and exclusion criteria is provided in the 
Supplementary Appendix.
Randomization and Blinding
We randomly assigned participants in a 1:1 ratio 
to receive either vaccine or placebo using an on-
line centralized randomization system. Partici-
pants were stratified according to region and age 
group (50 to 59, 60 to 69, and ≥70 years). Because 
the appearance of the reconstituted HZ/su vaccine 
differed from the placebo solution, injections 
were prepared and administered by study staff 
who did not participate in any study assessment. 
The investigators, participants, and those who 
were responsible for the evaluation of any study 
end point were unaware of whether vaccine or 
placebo had been administered.
Vaccination
The HZ/su vaccine contains 50 µg of recombi-
nant VZV glycoprotein E and the liposome-based 
AS01B adjuvant system containing 50 µg of 
3-O-desacyl-4′-monophosphoryl lipid A (MPL) and 
50 µg of Quillaja saponaria Molina, fraction 21 
(QS21, Antigenics, a wholly owned subsidiary of 
Agenus). Vaccine or placebo (0.9% saline solution) 
was administered (0.5 ml) into the deltoid mus-
cle at months 0 and 2. Starting 1 month after the 
administration of the second dose, participants 
were followed for at least 30 months through 
monthly contacts and through annual visits, 
which will continue for the entire study period 
(which is expected to be approximately 60 months).
Study End Points
The primary objective of the study was to evalu-
ate overall vaccine efficacy in reducing the risk of 
herpes zoster, as compared with placebo, in 
adults who were 50 years of age or older. Second-
ary objectives included determining the vaccine 
efficacy in reducing the incidence of herpes zos-
ter in each age group (50 to 59 years, 60 to 69 
years, and ≥70 years) and HZ/su safety and reac-
togenicity profiles. (A complete list of study ob-
jectives is provided in the Supplementary Appen-
dix.) Vaccine efficacy, as a percentage, was 
defined as 1 minus the ratio of the incidence of 
herpes zoster in the HZ/su group to the incidence 
in the placebo group, multiplied by 100.
Evaluation of Safety and Reactogenicity
A reactogenicity subgroup of participants record-
ed solicited injection-site reactions (pain, redness, 
and swelling) and systemic reactions (fatigue, 
fever, gastrointestinal symptoms, headache, myal-
gia, and shivering) on diary cards for 7 days after 
each vaccination. This subgroup included all par-
ticipants who were 70 years of age or older and 
randomly selected participants in the two other 
age groups (50 to 59 years and 60 to 69 years). 
The participants rated the intensity of the solic-
ited reactions on a scale from 0 (absent) to 3 
(preventing normal everyday activities). Unsolic-
ited adverse events were recorded for 30 days af-
ter each dose. Serious adverse events were re-
corded in all participants for up to 12 months 
after the second dose. Such events that were con-
sidered to be related to the study vaccine or study 
participation, any events resulting in death, and 
potentially immune-mediated diseases were eval-
uated in all participants over the entire study pe-
riod. (A full list of potentially immune-mediated 
diseases is provided in the Supplementary Ap-
pendix.)
Suspected Cases of Herpes Zoster 
A suspected case of herpes zoster was defined as 
new unilateral rash with pain (broadly defined to 
include allodynia, pruritus, or other sensations) 
that had no alternative diagnosis. Participants 
were instructed on how to recognize signs and 
symptoms of herpes zoster and to contact their 
study site immediately if any developed. They 
were required to record their symptoms on a spe-
cific diary card. Investigators were to examine 
suspected cases of herpes zoster within 48 hours, 
if possible.
Participants were followed for at least 90 days 
after the onset of the episode or until the rash 
resolved and the participant was pain-free for 
4 weeks. For each suspected case, the rash was 
photographed and samples were collected from 
three lesions to confirm the diagnosis of herpes 
zoster by means of real-time polymerase-chain-
reaction (PCR) assay targeting VZV ORF62.25 
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The lower limit of detection was 10 VZV DNA 
copies per reaction. A hierarchical case-definition 
algorithm was used to classify each suspected 
case. If the PCR assay was positive for VZV, the 
case was confirmed. If the PCR assay was nega-
tive for VZV and positive for β-actin (internal 
control), the case was classified as not herpes 
zoster. If all three samples were negative for 
both VZV and β-actin, or if lesion samples were 
not available, the final diagnosis was determined 
by unanimous agreement among the five mem-
bers of an ascertainment committee. The mem-
bers of this committee, who were unaware of 
PCR results and study-group assignments, re-
viewed all suspected cases on the basis of avail-
able clinical information, such as rash and pain 
evaluations, digital photographs, and clinical 
progress notes.
Statistical Analysis
Safety was analyzed in the total vaccinated co-
hort, which included all participants who re-
ceived at least one dose of HZ/su or placebo. Ef-
ficacy was analyzed in the total vaccinated cohort 
and in the modified vaccinated cohort (primary 
analysis); in the latter cohort, participants who 
Modified Vaccinated
Cohort
15,411 Underwent randomization
16,160 Participants were enrolled
749 Were excluded
726 Had Good Clinical Practice violation
23 Did not receive vaccine
7698 Were assigned to receive 
vaccine dose 1 (month 0)
7713 Were assigned to receive placebo
dose 1 (month 0)
337 Did not receive dose 2
4466 Completed diary cards
277 Did not receive dose 2
4460 Completed diary cards
7361 Received dose 2
(month 2)
7436 Received dose 2
(month 2)
17 Were excluded
4 Did not receive vaccine
according to protocol
9 Received wrong vaccine
4 Had diagnosis of HZ 
<30 days after dose 2
21 Were excluded
2 Did not receive vaccine
according to protocol
5 Received wrong vaccine
14 Had diagnosis of HZ 
<30 days after dose 2
7344 Were included in modified
vaccinated cohort
7415 Were included in modified
vaccinated cohort
Reactogenicity
Subgroup
Total Vaccinated
Cohort
Figure 1. Enrollment and Outcomes.
During the course of the study of the herpes zoster subunit (HZ/su) vaccine, two study centers were closed because 
of Good Clinical Practice violations. All participants who were enrolled in these centers were excluded from the statisti-
cal analyses. Because the ongoing study remains blinded, participants who withdrew from the study after dose 2 will 
be included in the modified vaccinated cohort until study completion.
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did not receive the second dose of vaccine or who 
received the diagnosis of herpes zoster within 
1 month after the second dose were excluded.
All significance tests were two-tailed; a P value 
of 0.05 or less was considered to indicate statis-
tical significance. All statistical analyses were 
performed with the use of SAS software, version 
9.2 (SAS Institute), and StatXact software, ver-
sion 8.1 (Cytel).
R esult s
Study Population
A total of 16,160 participants were enrolled be-
tween August 2, 2010, and July 21, 2011 (Fig. 1). 
Of these participants, 749 were excluded from 
the efficacy analyses, mostly owing to deviations 
from Good Clinical Practice standards at two 
study centers (involving 726 patients). The re-
maining 15,411 participants constituted the total 
vaccinated cohort for analysis; of these partici-
pants, 14,759 (95.8%) were included in the modi-
fied vaccinated cohort. Most participants re-
ceived two doses of the study vaccines (95.6% of 
HZ/su recipients and 96.4% of placebo recipients). 
A total of 8926 participants were assigned to the 
reactogenicity subgroup (4460 in the HZ/su group 
and 4466 in the placebo group).
Demographic characteristics were similar in 
the two study groups (Table 1). Most partici-
pants were from Europe (51.2%) and were white 
(71.8%) and female (61.2%). The mean age of 
participants at enrollment was 62.3 years.
Vaccine Efficacy
A total of 408 participants reported suspected 
herpes zoster. Of these participants, 244 (59.8%) 
were confirmed (220 [90.2%] on PCR assay and 
24 [9.8%] by the ascertainment committee) (Fig. 
S1 in the Supplementary Appendix). The concor-
dance between the PCR assay results and the 
committee assessment was 87%.
Of the 216 confirmed cases in the modified 
vaccinated cohort, 6 occurred in the HZ/su 
group and 210 in the placebo group after a mean 
follow-up of 3.2 years (Table 2). The overall inci-
dence of herpes zoster per 1000 person-years 
was 0.3 in the HZ/su group and 9.1 in the placebo 
group, for an overall vaccine efficacy of 97.2% 
(95% confidence interval [CI], 93.7 to 99.0; 
P<0.001) among participants who were 50 years 
of age or older. There was no significant differ-
ence in vaccine efficacy among the age groups 
(range, 96.6 to 97.9%). The overall vaccine effi-
cacy was similar in the total vaccinated cohort 
(96.2%; 95% CI, 92.7 to 98.3; P<0.001).
Safety and Reactogenicity
In the reactogenicity subgroup, solicited or unso-
licited symptoms within 7 days after vaccination 
were reported in 84.4% of participants in the 
HZ/su group and 37.8% in the placebo group 
(Table 3). Most symptoms were of mild-to-mod-
erate intensity, but 17.0% of HZ/su recipients and 
3.2% of placebo recipients reported symptoms 
that prevented normal everyday activities (grade 
3). These symptoms were mostly due to solicited 
injection-site reactions, which occurred in 81.5% 
of HZ/su recipients (grade 3 in 9.5%) and 11.9% 
of placebo recipients (grade 3 in 0.4%), and to 
systemic reactions, which occurred in 66.1% of 
HZ/su recipients (grade 3 in 11.4%) and 29.5% of 
placebo recipients (grade 3 in 2.4%). Pain was the 
most common injection-site reaction and was re-
ported in 79.1% of HZ/su recipients and 11.2% of 
placebo recipients. Myalgia was the most com-
mon systemic reaction and was reported in 
46.3% of HZ/su recipients and 12.1% of placebo 
recipients. Reactions were transient, with median 
durations ranging from 1 to 3 days for different 
solicited reactions among HZ/su recipients. For 
grade 3 reactions, the median duration was 1 day 
for all systemic reactions and pain and 2 days for 
redness and swelling. The overall frequencies of 
solicited reactions were similar after each dose, 
but grade 3 solicited systemic reactions were more 
frequent after the second dose (8.5%; 95% CI, 7.7 
to 9.4) than after the first dose (5.9%; 95% CI, 
5.2 to 6.6).
Within the first 30 days after vaccination, 231 
serious adverse events (103 in HZ/su recipients 
and 128 in placebo recipients) were reported in 
87 of 7698 HZ/su recipients (1.1%) and 97 of 
7713 placebo recipients (1.3%) in the total vac-
cinated cohort. Among these events, 4 partici-
pants (1 HZ/su recipient and 3 placebo recipients) 
had a serious adverse event that was considered 
to be related to vaccination by the investigators: 
hypotension with syncope, mononeuritis, neuro-
sensory deafness, and musculoskeletal chest pain. 
To date, after a mean follow-up of 3.5 years, the 
overall numbers and types of serious adverse 
events were similar in the HZ/su group (689 
participants [9.0%]) and the placebo group (686 
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participants [8.9%]), with the most frequent 
events being myocardial infarction and cardiac 
failure (Table S1 in the Supplementary Appen-
dix). The total numbers and types of potential 
immune-mediated diseases were also similar in 
the HZ/su group (78 participants [1.0%]) and the 
placebo group (97 participants [1.3%]) (Table S4 
in the Supplementary Appendix). A total of 341 
participants have died (167 HZ/su recipients 
[2.2%] and 174 placebo recipients [2.3%]) (Fig. 
S2 in the Supplementary Appendix).
Discussion
In this phase 3 efficacy trial of a subunit vaccine 
against herpes zoster, two doses of HZ/su ad-
ministered 2 months apart had a vaccine efficacy 
of 97.2%, as compared with placebo, in reducing 
the risk of herpes zoster in adults 50 years of age 
or older. The vaccine efficacy was similar among 
the three age groups. To date, no safety concerns 
have been identified, although solicited injection-
site and systemic reactions were more frequent in 
the HZ/su group.
The efficacy findings for HZ/su, with no sig-
nificant variation according to age, contrast with 
the results for Zostavax, which had lower effi-
cacy among participants who were 70 years of 
age or older (37.6%) than among those between 
the ages of 50 and 59 years (69.8%).7,8 The age-
independent efficacy of HZ/su is of clinical inter-
est, since the incidence and severity of herpes 
zoster are higher among older adults. HZ/su may 
thus provide a benefit to the population with 
the greatest medical need.2 In addition, the on-
going ZOE-70 study (ClinicalTrials.gov number, 
NCT01165229), which includes adults who are 
70 years of age or older and is being conducted 
at the same study centers as the ZOE-50 study, 
will provide an opportunity to assess vaccine ef-
ficacy against postherpetic neuralgia and other 
complications of herpes zoster.
Although no immunologic correlate of pro-
tection against herpes zoster has been identified, 
Table 1. Characteristics of the Participants at Baseline (Total Vaccinated Cohort).*
Characteristic
HZ/su Group
(N = 7698)
Placebo Group 
(N = 7713)
All Participants 
(N = 15,411)
Age
Mean (±SD) at first dose 62.4±9.0 62.3±9.0 62.3±9.0
Age group — no. (%)
50–59 yr 3645 (47.3) 3644 (47.2) 7,289 (47.3)
60–69 yr 2244 (29.2) 2246 (29.1) 4,490 (29.1)
70 yr or older 1809 (23.5) 1823 (23.6) 3,632 (23.6)
Sex — no. (%)
Female 4711 (61.2) 4713 (61.1) 9,424 (61.2)
Male 2987 (38.8) 3000 (38.9) 5,987 (38.8)
Race — no. (%)†
White 5532 (71.9) 5535 (71.8) 11,067 (71.8)
Black 140 (1.8) 130 (1.7) 270 (1.8)
Asian 1466 (19.0) 1470 (19.1) 2,936 (19.1)
Other 560 (7.3) 578 (7.5) 1,138 (7.4)
Region — no. (%)
Asia or Australia 1642 (21.3) 1642 (21.3) 3,284 (21.3)
Europe 3941 (51.2) 3948 (51.2) 7,889 (51.2)
Latin America 772 (10.0) 779 (10.1) 1,551 (10.1)
North America 1343 (17.4) 1344 (17.4) 2,687 (17.4)
* There were no significant differences between the groups. The percentages may not total 100 because of rounding.
† Race was self-reported.
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CD4+ and CD8+ T cells are believed to play a 
central role in preventing VZV reactivation.14,26-29 
In our study, the observation that vaccine effi-
cacy was maintained even among patients in the 
oldest age group, in conjunction with previous 
clinical data showing that HZ/su immunogenic-
ity decreases only minimally with increasing age, 
suggests that HZ/su can overcome immunose-
nescence to provide protection against herpes 
zoster.19,21,30-32 The immune response to HZ/su 
in both older persons and those with immuno-
suppression that was observed in earlier clinical 
studies might be attributed to the AS01B adjuvant 
system, which boosts VZV-specific memory im-
mune responses.20,33 Glycoprotein E adjuvanted 
with AS01B elicits higher glycoprotein-E–specific 
CD4+ T-cell and humoral immune responses 
than does unadjuvanted glycoprotein E, glycopro-
tein E adjuvanted with alum, or glycoprotein E 
adjuvanted with AS01 formulations containing 
lower amounts of the MPL and QS21 immuno-
stimulants.18,20,21 Therefore, although the small 
number of HZ/su recipients with herpes zoster 
in our study may prove insufficient to define an 
immunologic correlate of protection, future 
analyses of HZ/su immunogenicity will be of 
interest in explaining how an immune response 
targeting a single VZV antigen provides age-
independent protection against herpes zoster in 
older adults.
HZ/su was more reactogenic than placebo. 
Among HZ/su recipients, 81.5% had injection-site 
reactions, and 66.1% had systemic reactions. The 
most frequent reactions were pain at the injec-
tion site and myalgia, findings that are consis-
tent with the results of phase 1–2 studies.19,21-24 
Previous studies suggest that the antigen and 
the adjuvant both contribute to the difference in 
solicited injection-site and systemic reactions.17,21 
However, reactions were transient and mostly of 
mild-to-moderate intensity, and the fact that 
approximately 96% of the participants in the 
HZ/su and placebo groups received two doses of 
the study vaccine suggests that the reactogenicity 
of the HZ/su vaccine did not greatly affect par-
ticipants’ willingness to receive the second dose.
Table 2. Vaccine Efficacy against the First or Only Episode of Herpes Zoster Infection.*
Cohort and Age Group HZ/su Group Placebo Group
Vaccine  
Efficacy†
No. of 
Participants
No. of 
Confirmed 
Cases
Cumulative 
Follow-up 
Period ‡
Rate of 
Herpes 
Zoster
No. of 
Participants
No. of 
Confirmed 
Cases
Cumulative 
Follow-up 
Period‡
Rate of 
Herpes 
Zoster
person-yr
no./1000 
person-yr person-yr
no./1000 
person-yr % (95% CI)
Modified vaccinated  
cohort
All participants in cohort 7344 6 23,297.0 0.3 7415 210 23,170.5 9.1 97.2 (93.7–99.0)
50–59 yr 3492 3 11,161.3 0.3 3525 87 11,134.7 7.8 96.6 (89.6–99.3)
60–69 yr 2141 2 7,007.9 0.3 2166 75 6,952.7 10.8 97.4 (90.1–99.7)
70 yr or older 1711 1 5,127.9 0.2 1724 48 5,083.0 9.4 97.9 (87.9–100.0)
Total vaccinated cohort
All participants in cohort 7698 9 25,584.5 0.4 7713 235 25,359.9 9.3 96.2 (92.7–98.3)
50–59 yr 3645 3 12,244.9 0.2 3644 95 12,162.5 7.8 96.9 (90.6–99.4)
60–69 yr 2244 5 7,674.1 0.7 2246 83 7,581.8 10.9 94.1 (85.6–98.1)
70 yr or older 1809 1 5,665.5 0.2 1823 57 5,615.6 10.2 98.3 (89.9–100.0)
* The total vaccinated cohort included all vaccinated participants for whom data related to efficacy end points were available. The modified 
vaccinated cohort excluded participants who did not receive the second dose of vaccine or who received a confirmed diagnosis of herpes 
zoster within 1 month after the second dose. Efficacy was calculated by means of the Poisson method.
† P<0.001 for all efficacy comparisons with placebo. Vaccine efficacy in each age group was adjusted for region. Overall vaccine efficacy was 
adjusted for age group and region.
‡ Data were censored at the time of the first confirmed diagnosis of herpes zoster.
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Table 3. Adverse Events and Reactogenicity.*
Variable HZ/su Group Placebo Group
no. of participants/total no. % (95% CI) no. of participants/total no. % (95% CI)
Reactogenicity subgroup 4460 4466
Within 30 days after vaccination
Unsolicited report of adverse event 1308 29.3 (28.0–30.7) 1226 27.5 (26.1–28.8)
Grade 3 unsolicited report of adverse 
event†
208 4.7 (4.1–5.3) 151 3.4 (2.9–4.0)
Within 7 days after vaccination
Solicited or unsolicited report of adverse 
event
3765 84.4 (83.3–85.5) 1689 37.8 (36.4–39.3)
Grade 3 solicited or unsolicited report of 
adverse event†
760 17.0 (15.9–18.2) 145 3.2 (2.7–3.8)
Grade 3 solicited or unsolicited report of 
adverse event related to  
vaccination
694 15.6 (14.5–16.7) 83 1.9 (1.5–2.3)
Solicited report of injection-site reaction 3571/4382 81.5 (80.3–82.6) 522/4377 11.9 (11.0–12.9)
Pain 3464/4382 79.1 (77.8–80.2) 490/4377 11.2 (10.3–12.2)
Redness 1664/4382 38.0 (36.5–39.4) 59/4377 1.3 (1.0–1.7)
Swelling 1153/4382 26.3 (25.0–27.6) 46/4377 1.1 (0.8–1.4)
Grade 3 solicited report of injection-site 
reaction†
417/4382 9.5 (8.7–10.4) 16/4377 0.4 (0.2–0.6)
Solicited report of systemic reaction 2894/4375 66.1 (64.7–67.6) 1293/4378 29.5 (28.2–30.9)
Myalgia 2025/4375 46.3 (44.8–47.8) 530/4378 12.1 (11.2–13.1)
Fatigue 2008/4375 45.9 (44.4–47.4) 728/4378 16.6 (15.5–17.8)
Headache 1716/4375 39.2 (37.8–40.7) 700/4378 16.0 (14.9–17.1)
Shivering 1232/4375 28.2 (26.8–29.5) 259/4378 5.9 (5.2–6.7)
Fever 939/4375 21.5 (20.3–22.7) 132/4378 3.0 (2.5–3.6)
Gastrointestinal symptoms 788/4375 18.0 (16.9–19.2) 387/4378 8.8 (8.0–9.7)
Grade 3 solicited report of systemic  
reaction†
498/4375 11.4 (10.5–12.4) 106/4378 2.4 (2.0–2.9)
Total vaccinated cohort 7698 7713
Throughout study period
Serious adverse event‡ 689 9.0 (8.3–9.6) 686 8.9 (8.3–9.6)
Potential immune-mediated disease 78 1.0 (0.8–1.3) 97 1.3 (1.0–1.5)
Death 167 2.2 (1.9–2.5) 174 2.3 (1.9–2.6)
Within 30 days after vaccination
Serious adverse event‡ 87 1.1 (0.9–1.4) 97 1.3 (1.0–1.5)
Serious adverse event related to vaccina-
tion§
1 0.0 (0.0–0.1) 3 0.0 (0.0–0.1)
Death 8 0.1 (0.0–0.2) 7 0.1 (0.0–0.2)
* Additional details regarding adverse events are provided in Tables S1 through S4 and Fig. S2 in the Supplementary Appendix.
† Redness and swelling at the injection site were scored as 0 for reactions of less than 20 mm diameter, 1 for those between 20 mm and 50 mm, 
2 for those of more than 50 mm to 100 mm, and 3 for those more than 100 mm. Temperature was scored as 0 for less than 37.5°C, 1 for 
37.5 to 38.0°C, 2 for 38.1 to 39.0°C, and 3 for more than 39.0°C. (The preferred route for recording temperature was oral.) All other symp-
toms were scored as 0 for absent, 1 for easily tolerated, 2 for interfering with normal activity, and 3 for preventing normal activity.
‡ Serious adverse events were defined as events that resulted in death, were life-threatening, required hospitalization or prolongation of exist-
ing hospitalization, and resulted in disability or incapacity.
§  The four serious adverse events that were considered to be related to vaccination by the investigators were hypotension with syncope, 
mononeuritis, neurosensory deafness, and musculoskeletal chest pain.
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Although the interpretation of the safety data 
are subject to limitations resulting from the need 
to maintain participant-level study blinding, at 
present, no safety concerns have been raised by 
either the independent monitors who have criti-
cally reviewed and analyzed the unblinded safety 
data during the course of the study or the spon-
sor’s firewall team, who reviewed and con-
firmed the results presented here. Exacerbation 
or triggering of immune-mediated diseases in 
susceptible persons is a hypothetical concern for 
vaccines containing new adjuvants such as AS01B 
because of their immunostimulatory effects.16,34,35 
Through careful monitoring during the course 
of the study, we found no evidence that immune-
mediated diseases occurred more frequently 
among HZ/su recipients than among placebo 
recipients. The safety of HZ/su will continue to 
be monitored in the ongoing ZOE-50 and ZOE-70 
studies.
In conclusion, the HZ/su vaccine significantly 
reduced the risk of herpes zoster among adults 
who were 50 years of age or older, and overall 
efficacy was well preserved among participants 
who were 70 years of age or older.
Supported by GlaxoSmithKline Biologicals.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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